Table 3. Multiple linear regression models of factors influencing therapeutic efficacy of denosumab in patients with SLE.

Predictors	Lumbar spine				Total hip				Femur neck
	T-score difference		aBMD change (%)		T-score difference		aBMD change (%)		T-score difference		aBMD change (%)
	β	P value	β	P value	β	P value	β	P value	β	P value	β	P value
BMI, kg/m2	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	0.160	0.110
SLEDAI-2K score	−0.070	0.582	−0.047	0.718	N/A	N/A	N/A	N/A	−0.010	0.037*	−0.238	0.012*
Hydroxychloroquine use	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	−0.074	0.031*	−1.341	0.042*
Prior osteoporosis treatment	−0.070	0.585	−0.040	0.759	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CTx, ng/mL	0.197	0.141	0.240	0.071	N/A	N/A	0.130	0.360	N/A	N/A	N/A	N/A
Baseline BMD value	−0.170	0.001**	−21.484	0.001**	−0.058	0.008**	−19.413	0.002**	N/A	N/A	N/A	N/A
R2	0.211		0.202		0.044		0.182		0.084		0.106
Adjusted R2	0.195		0.186		0.038		0.165		0.066		0.087

N/A: Not applicable. Baseline BMD value: T-score or aBMD value at denosumab initiation for the respective site.

^*P<0.05, **P<0.01.

aBMDareal BMDBMDbone mineral densityBMIbody mass indexCTxC-telopeptide of collagen type 1N/Anot applicableSLEDAI-2KSLE Disease Activity Index 2000